CompaniesHealthcare & FitnessPharmaceuticalsPrint articleBrief: BionomicsBionomics has completed the second Phase I clinical trial of its anti-anxiety compound, BNC210.Jun 21, 2010 – 4.26pmSaveLog in or Subscribe to save articleShareCopy linkCopiedEmailLinkedInTwitterFacebookCopy linkCopiedShare via...Gift this articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Login Bionomics has completed the second Phase I clinical trial of its anti-anxiety compound, BNC210. The aim of this trial was to determine whether administration of BNC210 with food alters blood levels of the drug.Loading...SaveLog in or Subscribe to save articleShareCopy linkCopiedEmailLinkedInTwitterFacebookCopy linkCopiedShare via...Gift this articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? LoginLicense articleIntroducing your NewsfeedFollow the topics, people and companies that matter to you.Find out moreRead MorePharmaceuticalsBionomics LimitedLatest In Healthcare & fitnessFetching latest articlesMost Viewed In Companies
